02 October 2023
02 October 2023
CEO of H1 Ariel Katz’s mission is ‘to connect the world to the right doctor’ with a focus on connecting sponsors with the right PIs.
Venetoclax combo therapy did not reach statistical significance in improving progression-free survival in multiple myeloma patients.
The drug is predicted to dominate the earlier HER2-negative second-line settings in the future.
Novartis unveiled positive top-line Phase III results for iptacopan in IgA nephropathy and plans talks with the FDA to obtain accelerated approval in 2024.
Multinational Philips is alleged to have illegally hidden reports of catastrophic device failure in their respirators for over a decade.
The insomnia market is heavily genericised, creating a difficult competitive environment for new drug products.
The bispecific antibody had an overall response rate of 71%, with a probability of 89% of the participants maintaining the response over a six-month period.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
